Results 151 to 160 of about 19,808 (220)

Age-Related Outcomes of [¹⁷⁷Lu]Lu-PSMA Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer: A Retrospective Analysis. [PDF]

Cancers (Basel)
Schweigert N, Strewinsky N, Köhler D, Lehnert W, Ekrutt J, Karimzadeh A, Klutmann S, von Amsberg G, Sauer M.   +8 more
europepmc   +1 more source

Tolerability of PSMA radioligand therapy in metastatic prostate cancer patients with baseline mild to moderate leukopenia. [PDF]

EJNMMI Res
Bastian MB, Speicher T, Blickle A, Burgard C, Bastian JLD, Bartholomä M, Schaefer-Schuler A, Maus S, Ezziddin S, Rosar F.   +9 more
europepmc   +1 more source

Complications and outcomes of radioligand therapy in patients with neuroendocrine neoplasms depending on the baseline glomerular filtration rate. [PDF]

Eur J Nucl Med Mol Imaging
Durma AD, Saracyn M, Jóźwik-Plebanek K, Brodowska-Kania D, Kołodziej M, Żmudzki W, Kamiński G.   +6 more
europepmc   +1 more source

Safety and efficacy of ¹⁷⁷Lu-FAPI-XT radioligand therapy in patients with advanced sarcoma and other cancer entities: first-in-human, dose-escalation study. [PDF]

Eur J Nucl Med Mol Imaging
Liu H, Guo R, Zhang X, Ji H, Sun S, Sun S, Liu J, Yang Z, Wang R.   +8 more
europepmc   +1 more source

PSMA PET Imaging in the Management of Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Radioligand Therapy. [PDF]

Target Oncol
Kuo PH, Calais J, Crosby M.
europepmc   +1 more source

An Update on DOTA-Peptides PET Imaging and Potential Advancements of Radioligand Therapy in Intracranial Meningiomas. [PDF]

Life (Basel)
Benfante V, Vetrano IG, Ali M, Purpura P, Gagliardo C, Feraco P, Longo C, Bartolotta TV, Toia P, Calisto O, Comelli A, Midiri M, Alongi P.   +12 more
europepmc   +1 more source

Neoadjuvant ¹⁷⁷Lutetium-PSMA-617 Radioligand Therapy for High-Risk Localized Prostate Cancer: Rationale, Early Clinical Evidence, and Future Directions. [PDF]

Cancers (Basel)
Kwon WA, Joung JY.
europepmc   +1 more source

The role of PSMA-based radioligand therapy in hormone-sensitive prostate cancer. [PDF]

Eur J Nucl Med Mol Imaging
Laudicella R, Bauckneht M, Burger IA, Cacciola A, Fanti S, Farolfi A, Ficarra V, Iagaru A, Liberini V, Pergolizzi S, Santo G, Virgolini I, Minutoli F, Baldari S.   +13 more
europepmc   +1 more source

Advanced Image Analysis to Select Patients for Prostate Specific Membrane Antigen Radioligand Therapy and Assess Treatment Response. [PDF]

Adv Radiat Oncol
Floberg JM, Kyriakopoulos CE, Cho SY.
europepmc   +1 more source